Literature DB >> 16765271

A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients.

S D Walter1, Gordon Guyatt, Victor M Montori, R Cook, K Prasad.   

Abstract

BACKGROUND AND OBJECTIVES: Development of a new method of analysis to evaluate the acceptability of (or preferences for) the treatments in a randomized trial, and the benefit of treatment among compliers.
MATERIALS AND METHODS: We characterize trial participants through the groups who would: accept either treatment if offered (compliers); refuse one treatment but accept the other if it is offered to them (two groups of preferers); or prefer one treatment and insist on it if it is not offered to them initially (two groups of insisters).
RESULTS: We show that in our framework, one can always estimate the proportions of patients in these five preference groups. However, constraints are required to estimate the corresponding outcome rates, and thus estimate the treatment effect in the compliers. We propose two possible sets of constraints and illustrate them by numerical examples.
CONCLUSIONS: The traditional intention-to-treat analysis avoids biases associated with the alternative per-protocol or as-treated approaches, but it provides imperfect information about the expected treatment effect among patients who are committed to taking the treatment. Many physicians and patients want to know the expected benefit if they adhere to the therapy. Our preference-based analysis provides an estimate of treatment benefit among such patients.

Entities:  

Mesh:

Year:  2006        PMID: 16765271     DOI: 10.1016/j.jclinepi.2005.11.016

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  4 in total

1.  Estimating causal effects using prior information on nontrial treatments.

Authors:  Simon J Bond; Ian R White
Journal:  Clin Trials       Date:  2010-09-03       Impact factor: 2.486

2.  An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials.

Authors:  Jeremy B Sussman; Rodney A Hayward
Journal:  BMJ       Date:  2010-05-04

3.  Authors' reply: Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019).

Authors:  Moonseong Heo; Paul Meissner; Alain H Litwin; M Diane McKee; Alison Karasz; Earle C Chambers; Ming-Chin Yeh; Judith Wylie-Rosett
Journal:  Stat Methods Med Res       Date:  2018-04-10       Impact factor: 3.021

4.  Effects of varenicline therapy in combination with advanced behavioral support on smoking cessation and quality of life in inpatients with acute exacerbation of COPD, bronchial asthma, or community-acquired pneumonia: A prospective, open-label, preference-based, 52-week, follow-up trial.

Authors:  Alexios Politis; Vasileios Ioannidis; Konstantinos I Gourgoulianis; Zoe Daniil; Chrissi Hatzoglou
Journal:  Chron Respir Dis       Date:  2017-11-08       Impact factor: 2.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.